Biotech Values

[iwfal]

MNTA -

The recent launch of a competitive generic Lovenox triggered a change in the contract terms with our collaboration partner, Sandoz, from a hybrid profit share/royalty to a royalty.

The important point. I think the chance of settlement drops precipitously starting now because it is difficult to unscramble the egg (e.g. raise prices after market withdrawal - especially when the AG enters.) and WPI clearly is not playing with a full deck (or being pushed over the cliff by Amphastar).